NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort (e): Sonstiges Mainz Biomed gibt Aktienzusammenlegung bekannt 29.11 ...
From clinical developments to an upcoming FDA trial anticipated in 2025, Mainz Biomed NV MYNZ, the molecular genetics diagnostic company, is making headway in growing its business on its path to ...
In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with ...
BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company ...
H.C. Wainwright downgraded Mainz Biomed (MYNZ) to Neutral from Buy without a price target after the company presented key data from the eAArly DETECT study, showing 97% sensitivity for colorectal ...
Short interest in Mainz Biomed NV (NASDAQ:MYNZ) decreased during the last reporting period, falling from 1.70M to 1.52M. This put 8.25% of the company's publicly available shares short.
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback